Consolidated Entities and Acquisitions - Theravance Respiratory Company, LLC (Details) - USD ($) $ in Thousands		3 Months Ended		12 Months Ended
	Jul. 20, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Income statements
Total revenue		$ 76,372	$ 90,059
Income tax expense, net		6,275	6,860
Net income		34,865	37,858
Royalty revenue
Income statements
Total revenue		$ 56,858	90,059
Theravance Respiratory Company, LLC
CONSOLIDATED ENTITIES
Ownership interest in LLC				15.00%
Proceeds from sale of economic interest under Equity Purchase Agreement	$ 277,500
Contingent sales based milestone payment	50,000
Cash distribution	4,400
Equity method investments	$ 39,400
Income statements
Operating expenses			198
Income from operations			29,111
Income tax expense, net			1
Changes in fair values of equity and long-term investments			429
Net income			29,541
Theravance Respiratory Company, LLC | Royalty revenue
Income statements
Total revenue			$ 29,309